UCB has gained FDA approval for BIMZELX® (bimekizumab-bkzx), making it the first IL-17A and IL-17F blocker for adults suffering from moderate to severe hidradenitis suppurativa.

Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with HFpEF and obesity.

Adicet has started recruiting participants for the Phase 1 clinical trial of ADI-270 in patients with metastatic or advanced clear cell renal cell carcinoma.

Pharmanovia enters a new licensing deal with Lindis Biotech to market Catumaxomab for the rare disorder malignant ascites.

Merck has launched a Phase 3 trial for subcutaneous pembrolizumab combined with berahyaluronidase alfa, achieving its primary goals.

Otsuka shared new information about Sibeprenlimab, an experimental monoclonal antibody aimed at treating IgA nephropathy in adults.

Nurix Therapeutics showcases early data on two programs for autoimmune and inflammatory diseases, NX-5948 and GS-6791, at ACR Convergence 2024.

Fate Therapeutics Showcases FT522, an Off-the-Shelf, ADR-Equipped CAR NK Cell Candidate, at the 2024 ACR Convergence.

Allogene Therapeutics shares preclinical findings for ALLO-329, a dual CAR T targeting CD19 and CD70, aimed at treating autoimmune diseases.

Lilly's tirzepatide lowered the chance of worsening heart failure events by 38% in adults who have HFpEF and obesity.

AbelZeta showcases preliminary findings on C-CAR168 for autoimmune disease treatment at ACR Convergence 2024.

Rona Therapeutics showcased encouraging Phase 1 findings for RN0191, an innovative siRNA treatment aimed at PCSK9, during the 2024 AHA Scientific Sessions.